Document:

Orgenesis Inc.: Exhibit 10.1 - Filed by newsfilecorp.com

RELEASE AGREEMENT 

     THIS AGREEMENT is dated
and effective as of the 18th day of November 2016 by and between
Orgenesis Maryland Inc. (the “Company”) and Scott Carmer (the
“Employee”). 

WITNESSETH 

     WHEREAS, Employee
currently serves as the Company's Chief Executive Officer under that certain
Employment Agreement dated as of July 23, 2014 (the "Employment Agreement"); and

     WHEREAS, Employee desires
to resign from his employment under the Employment Agreement, and the Company is
agreeable to such resignation, in accordance with the terms and conditions set
forth herein. 

     NOW, THEREFORE, in
consideration of the mutual promises and covenants contained in this agreement
the Parties hereby agree as follows: 

1. Termination of Employment Agreement. Upon execution
hereof by both Parties, the Employment Agreement shall automatically and without
any further action on the part of the Parties be terminated, except to the
extent otherwise provided herein. By his execution of this Agreement, and
without any further action, Employee hereby resigns, effective immediately, from
any positions he holds with the Company including as an officer and executive.

2. Representations and Undertakings by Employee 

     In consideration of the releases
by the Company contained herein, Employee hereby agrees, represents and
covenants as follows: 

     a) Employee acknowledges and
agrees that Part 3 (Confidential Information and Intellectual Property) and Part
4 (Non-Competition and Non-Solicitation) of the Employment Agreement shall
continue in full force and effect in accordance with their terms. Nothing
contained in this Agreement shall be construed or interpreted as a waiver by the
Company of any right or remedy available under Parts 3 and 4 of the Employment
Agreement in the event of a breach occurring after the date of this
Agreement. 

     b) Employee shall forthwith
return to the Company all Company non-public information in his possession,
control or under his influence. 

     c) Employee acknowledges and
agrees that the undertakings and release by Company contained in this Agreement
are intended to be made in lieu of any amounts, now or in the future, payable by
Company to Employee under the terms of the Employment Agreement and in full
satisfaction of all claims by Employee to any payments and accrued salary owing
from the Company (and its affiliates, officers, directors, shareholders,
employees, agents, attorneys, insurers, successors and assigns) in connection
with any services provided by Employee including under the Employment
Agreementor to any other rights or privilege. 

     d) The Employee shall be
reasonably available for telephone consultations through the end of December
2016 if so determined by the Company to assist the Company with an orderly
transition of his duties under the Employment . 

1 

2. Representations and Undertakings by the Company 

In consideration of the undertakings by the Employee contained
herein, Company hereby agrees, represents and covenants that Employee shall be
entitled to exercise stock options to purchase a total of 1,641,300 shares of
common stock of Orgenesis Inc. (the “Parent”), the parent company of the
Company, previously granted to Employee on or about April 27, 2016 through their
specified exercise termination date. To the extent any part of such award has
not vested as of the date hereof, then such award shall be deemed fully vested.

3. Releases 

     3.1 In consideration of the
agreements of Company under this Agreement, and the release contained in Section
3.2 below, Employee (and each of his respective, attorneys, agents, heirs,
successors, executors, personal representatives and assigns) does hereby
absolutely and unconditionally waive, release and forever discharge Company (and
its affiliates, officers, directors, shareholders, employees, agents, attorneys,
insurers, successors and assigns) from any claims, demands, obligations,
liabilities, rights, causes of action and damages, whether liquidated or
unliquidated, absolute or contingent, known or unknown, arising prior to or
concurrent with the date hereof, including, without limitation, any claim under
the Employment Agreement (including for accrued and unpaid salary through to
this date), any claims under any labor laws and regulations including claims for
wrongful termination, claims with respect to the stock options or claims with
respect to any other payment required under law. The foregoing release shall not
be construed as a waiver by Employee of the compliance by the Company with its
undertakings contained in this Agreement or of the Parent with respect to the
option referred to in Section 2.

     3.2 In consideration of the
undertakings of Employee hereunder and the release in Section 3.1 above and the
hereof the Company (and its officers, directors, shareholders, employees,
attorneys, agents, successors, and assigns) does hereby absolutely and
unconditionally waive, release and forever discharge Employee and his
respective, agents, attorneys, insurers, successors, executors and assigns, from
any claims, demands, obligations, liabilities, rights, causes of action and
damages, whether liquidated or unliquidated, absolute or contingent, known or
unknown, arising prior to or concurrent with the date hereof. The foregoing
release shall not be construed as a waiver by the Company of the compliance by
Employee of his undertakings contained in this Agreement.

4. Successors and Assigns. Except as otherwise provided
in this Agreement, all the terms and provisions of this Agreement shall be upon,
and shall inure to the benefit of, the Parties hereto and their respective
heirs, personal representatives, successors and assigns. 

5. Counterparts. This Agreement may be executed in one
or more counterparts, each of which shall be deemed an original, but all of
which together shall constitute one and the same instrument. 

6. Governing Law; Jurisdiction and Forum. This
Agreement, its interpretation, validity, construction, enforcement and effect
shall be governed by and construed under the laws of the State of Maryland
without reference or effect to the principles of conflict of laws. Each of the
Parties consents to the jurisdiction of the appropriate state or federal court
in the State of Maryland in connection with any dispute arising under this
Agreement and hereby waives, to the maximum extent permitted by law, any
objection, including any objection based on forum non conveniens, to the
bringing of any such proceeding in such jurisdictions. 

7. Non-Disparagement. 

2 

     Neither of the Parties (and their
respective heirs, personal representatives, successors, affiliates, subsidiaries
or officers), shall disparage the other Party hereto or their businesses.

8. Further Assurances. 

     Each of the parties agree to
execute all such documents and do all acts and things reasonably required to
effectively carry out the provisions of this Agreement. 

     IN WITNESS WHEREOF, each
of the parties has set forth its/ his signature as of the date first written
above. 

	 Orgenesis Maryland Inc. 	 	 
	 	 	 
	/s/ Vered Caplan	 	/s/
      Scott Carmer
	Vered Caplan 	 	Scott Carmer 
	Chairperson 	 	  

AGREED AND ACCEPTED as to the terms of Section 2 hereof
As of November 18, 2016 

Orgenesis Inc. 

	By: 	/s/
      Vered Caplan	 
	  	  	 
	Name: 	Vered Caplan 	 
	Title: 	Chief Executive Officer 	 

3Orgenesis Inc.: Exhibit 10.2 - Filed by newsfilecorp.com

STRATEGIC ADVISORY AGREEMENT 

     This Strategic Advisory Agreement
(this “Agreement”), dated effective as of November 18, 2016, (the
“Effective Date”) is entered into by and between Orgenesis Inc., a
Nevada corporation (herein referred to as the “Company”) and Scott
Carmer (herein referred to as the “Advisor”). Advisor and the Company
are sometimes referred to herein individually as a “Party,” and
collectively as the “Parties.” 

RECITALS 

     WHEREAS, Advisor has
previously served as the CEO of the Company’s wholly-owned subsidiary, Orgenesis
Maryland, Inc. (“Subsidiary”), from which position Advisor has resigned
as of November 18, 2016; 

     WHEREAS, Advisor has
experience in strategic planning, clinical development, commercialization and
overall business development in the regenerative medicine industry; and 

     WHEREAS, the Company
desires to engage the services of Advisor to provide the services outlined
below. 

     NOW THEREFORE, in
consideration of the promises and the mutual covenants and agreements
hereinafter set forth, the Parties hereto covenant and agree as follows: 

1. Term of Consultancy. The Company hereby engages
Advisor on a non-exclusive basis for the Term, as defined below, to provide the
Services defined below . The Company hereby agrees to retain Advisor in a
consulting capacity, upon the terms and conditions set forth herein, for a term
of one (1) year from the Effective Date (the “Term”). 

2. Duties of Advisor. Advisor shall, on a non-exclusive
basis, serve as an advisor and provide the Company with the following services
(collectively, the “Services”) during the Term hereof: 

     2.1 Consult with and assist the
Company in identifying and evaluating the most appropriate strategic and
clinical plans to develop and commercialize its technologies; 

     2.2 Make himself reasonably
available, at the Company’s request, to attend meetings or for conversations to
discuss the business of the Company with potential investors and/or strategic
partners; 

     2.3 At the Company’s request,
review business plans, strategies, mission statements, budgets, proposed
transactions and other plans for the purpose of advising the Company on the most
viable avenues for growth and business development; and 

     2.4 Advise the Company as
requested in any other area where Advisor may be able in order to help the
Company execute its business plan. 

3. Allocation of Time and Energies. Advisor hereby
promises to perform and discharge faithfully the responsibilities which may be
assigned to Advisor from time to time by the officers and duly authorized
representatives of the Company in connection with the conduct of its activities
herein, so long as such activities are in compliance with applicable securities
laws and regulations.

4. Remuneration. For undertaking this engagement and for
other good and valuable consideration, the Advisor agrees that the Company’s
agreement to extend the Advisor’s right to exercise the fully vested options
granted to him in connection with his pervious employment by the Subsidairy, as
specified in that certain Release Agreement entered into by the the
Advisor and Company dated November 18, 2016 shall qualify as full consideration
for services to be performed by Advisor hereunder. 

1

5. Non-Assignability of Services. Advisor’s Services
under this Agreement may be assigned by the Company to any entity with which the
Company merges or which acquires the Company or substantially all of its assets
wherein the Company becomes a minority constituent of the combined company.
Advisor shall not assign its rights or delegate its duties hereunder without the
prior written consent of the Company. 

6. Expenses. The Company shall be responsible for all
expenses relating to Advisor’s Services under this Agreement as may be incurred
from time to time, subject to pre-approval by the Company. 

7. Indemnification. The Company warrants and represents
that all oral communications, written documents or materials furnished to
Advisor by the Company with respect to financial affairs, operations,
profitability and strategic planning of the Company are accurate in all material
respects and Advisor may rely upon the accuracy thereof without independent
investigation. The Company will protect, indemnify and hold harmless Advisor
against any claims or litigation including any damages, liability, cost and
reasonable attorney’s fees as incurred with respect thereto resulting from
Advisor’s communication or dissemination of any said information, documents or
materials excluding any such claims or litigation resulting from Advisor’s
communication or dissemination of information not provided or authorized by the
Company. Advisor warrants and represents that all oral communications, written
documents, or materials furnished to third parties by Advisor, originating with
Advisor and to the extent not mirroring material furnished by the Company, shall
be accurate in all material respects. The Advisor will protect, indemnify and
hold harmless the Company against any claims or litigation including any
damages, liability, cost and reasonable attorneys fees as incurred with respect
thereto resulting from any claims or litigation resulting from Advisor’s
communication or dissemination of information not provided or authorized by the
Company, or from Advisor’s negligence or misconduct. The Advisor will not trade
in the securities of the Company while in possession of material information
about the Company that has not been publicly disclosed by the Company.

8. Development Rights & Confidential
Information 

     8.1 Development Rights.
Advisor agrees and declares that all proprietary information including but not
limited to trade secrets, know-how, patents and other rights in connection
therewith developed by or with the contribution of Advisor's efforts during the
term of his provision of Services to the Company, shall be the sole property of
the Company. Upon the Company's request (whenever made), Advisor shall execute
and assign to the Company all the rights in the proprietary information.

     8.2 Confidentiality. 

     (a) The
term "Information" as used in this Article means any and all confidential and
proprietary information, designated as such by the Company, including but not
limited to any and all specifications, formulae, prototypes, software design
plans, computer programs, and any and all records, data, methods, techniques,
processes and projections, plans, marketing information, materials, financial
statements, memoranda, analyses, notes, and other data and information (in
whatever form), as well as improvements and know-how related thereto, relating
to the Company or its products. Information shall not include information that
(a) subject to Article 8.1 was already known to or independently developed by
Advisor prior to its disclosure as demonstrated by reasonable and tangible
evidence satisfactory to the Company; (b) shall have appeared in any printed
publication or patent or shall have become part of the public knowledge except
as a result of breach of this Agreement by the Advisor or similar agreements by
other Advisor’s or Company employees (c) shall have been
received by the Advisor from another person or entity having no obligation of
confidentiality to the Company or (d) is approved in writing by the Company for
release by the Advisor. 

2

     (b)
Advisor agrees to hold in trust and confidence all Information disclosed to it
and further agrees not to exploit or disclose the Information to any other
person or entity or use the Information directly or indirectly for any purpose
other than for Advisor’s work with the Company. 

     (c)
Advisor agrees to disclose the Information only to persons necessary in
connection with Advisor’s work with the Company and who have undertaken in
writing the same confidentiality obligations set forth herein in favor of the
Company. 

     (d)
Advisor acknowledges and agrees that the Information furnished hereunder is and
shall remain proprietary to the Company. Unless otherwise required by statute or
government rule or regulation, all copies of the Information, shall be returned
to the Company immediately upon request without retaining copies thereof.

     8.3 During Advisor’s provision of
Services to the Company Advisor will not improperly use or disclose any
confidential information or trade secrets, if any, of any former client or
employer or any other person to whom Advisor has an obligation of
confidentiality, and Advisor will not bring onto the premises of the Company any
unpublished documents or any property belonging to any former employer or any
other person to whom Advisor has an obligation of confidentiality unless
consented to in writing by that former employer or person. To the extent that
Company consents to receipt of confidential information of third parties
obtained by Advisor, the Company agrees to hold in trust and confidence all such
information disclosed to it and further agrees not to exploit or disclose such
information to any other person or entity or use the information directly or
indirectly for any purpose other than for Advisor’s work with the Company 

     8.4 Advisor's undertakings herein
under Article 8 shall survive espiration or termination of this Agreement.

9. Representation. The Company and Advisor represent to
one another that each has consulted with independent legal counsel and/or tax,
financial and business advisors, or was given an adequate opportunity to do so
prior to the execution of this Agreement, to the extent deemed necessary. 

10. Status as Independent Contractor. Advisor’s
engagement pursuant to this Agreement shall be as independent contractor, and
not as an employee, officer or other agent of the Company. Neither Party to this
Agreement shall represent or hold itself out to be the employer or employee of
the other. Neither the Company nor Advisor possesses the authority to bind each
other in any agreements without the express written consent of the entity to be
bound. 

11. Attorney’s Fee. If any arbitration is brought for
the enforcement or interpretation of this Agreement, or because of an alleged
dispute, breach, default or misrepresentation in connection with or related to
this Agreement, the successful or prevailing Party shall be entitled to recover
reasonable attorneys’ fees and other costs in connection with that action or
proceeding, in addition to any other relief to which it or they may be entitled.

12. Waiver. The waiver by either Party of a breach of
any provision of this Agreement by the other Party shall not operate or be
construed as a waiver of any subsequent breach by such other Party. 

3

13. Notices. All notices, requests, and other
communications hereunder shall be deemed to be duly given if sent by U.S. mail,
postage prepaid, addressed to the other Party at the address as set forth herein
below: 

	 	To the Company: 	Orgenesis Inc. 
	 	  	
      20271 Goldenrod Lane 

	 	  	
      Germantown, MD 20876 

	 	  	
      Attn: Vered Caplan, Chief Executive Officer 

	 	  	
      Phone: 011-972-54-4301034 

	 	  	
      Email: vered.c@orgenesis.com 

	 	  	
       

	 	To Advisor: 	
      Scott Carmer 

	 	 	
      4817 Essex Avenue  

	 		
      Bethesda, MD 20815  

	 	  	
      Phone: (301) 204-1983 

	 	  	
      Email: spcarmer46@gmail.com 

14. Governing Law. This Agreement shall be governed by
and construed solely in accordance with the laws of the State of New York,
without giving effect to the conflict or choice of law principles thereof.

15. Termination. This Agreement may be terminated by the
Company on Thirty (30) days written notice to the Advisor at any time without
prejudice to any other rights or remedies either Party may have. The Agreement
may be terminated by Advisor on Thirty (30) days written notice only in
the event of a change in the business, properties, operations or financial
condition or prospects of the Company that adversely and substantially affects
the ability of Advisor to perform the Services hereunder.

16. Arbitration. Any controversy or claim arising out of
or relating to this Agreement, or the alleged breach thereof, or relating to
activities or remuneration under this Agreement, shall be settled by binding
arbitration in New York, whether commenced by the Company or Advisor, in
accordance with the applicable rules of the American Arbitration Association,
Commercial Dispute Resolution Procedures, and judgment on the award rendered by
the arbitrator(s) shall be binding on the Parties and may be entered in any
court having jurisdiction.

17. Entire Agreement; Execution in Counterparts. This
Agreement contains the entire Agreement of the Parties hereto as to the subject
matter hereof and may be modified or changed only by an agreement in writing
sighed by the Party against whom enforcement of any modification or change is
sought. If any provision of this Agreement is declared void, such provision
shall be deemed severed by this Agreement, which shall otherwise remain in full
force and effect. This Agreement may be executed in counterparts. 

4

     IN WITNESS WHEREOF, the Parties
have executed this Agreement as of the day and year first above written. 

AGREED TO: 

ORGENESIS INC. 

	By: 	/s/  Vered Caplan	 
	Name: 	Vered Caplan, Chief Executive
      Officer 	 

SCOTT CARMER 

	By: 	/s/  Scott Carmer 	 
	Name: 	Scott Carmer 	 
	Title: 	Individual 	 

5

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00264-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00264-of-00352.parquet"}]]